Business Context and Reporting Period
This Form 8-K is a current report filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on September 18, 2014. The filing discloses the appointment of a new Chief Financial Officer and Treasurer and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation:
- Base Salary: $315,000 annually.
- Discretionary Bonus: Up to 35% of base salary.
- Stock Option Grant: 224,000 shares at an exercise price of $15.67 per share.
- Severance: Six months of base salary and COBRA health insurance premiums upon termination without cause or resignation for good reason.
Material Changes
The primary material change reported is the leadership transition in the finance department:
- Appointment: Jeffrey E. Young was appointed Chief Financial Officer and Treasurer effective September 17, 2014.
- Departure: Christopher Bleck was replaced as Principal Accounting Officer and Principal Financial Officer as of September 17, 2014.
- Compensation Structure: Implementation of a new offer letter including a stock option grant outside the 2012 Stock Incentive Plan, granted as an inducement for employment under NASDAQ Listing Rule 5635(c)(4).
Outlook, Risks, and Unusual Items
The filing contains no forward-looking guidance, market outlook, or discussion of general business risks. Specific contractual terms and contingencies include:
- Stock Option Vesting: Options vest over four years (25% on the first anniversary, then 6.25% quarterly). Full acceleration occurs in a change of control if employment is terminated without cause or resigned for good reason within one year.
- Employment Terms: Employment is at-will and may be terminated by either party at any time with or without cause.
- Restrictive Covenants: Mr. Young has signed Invention and Non-Disclosure Agreements, as well as Non-Competition and Non-Solicitation Agreements.
Investor Verification Checklist
- Verify the exact terms of the Offer Letter (Exhibit 10.1) regarding performance goals for the discretionary bonus.
- Confirm the impact of the stock option grant on the company's existing equity plan and potential dilution.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the leadership change.
- Note that the filing text does not provide current financial statements or liquidity metrics.